ClinicalTrials.gg
TerminatedNCT04501952Updated Nov 16, 2021Results posted

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting

A Phase 3 interventional study of RDV and Placebo to Match RDV in COVID-19, sponsored by Gilead Sciences. Terminated at 104 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-16.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
584
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing remdesivir in COVID-19 — 6 open to participants now, 9 under way, 3 of them phase 3. remdesivir · COVID-19.

Enrollment
15th of 40
584 · median 283
Started
2020
with 26 others
Phase 3
17 of 40
2 open now
Registered
18th of 40
by date
Lead sponsor
6 of 40
Gilead Sciences

Among the 40 studies testing remdesivir in COVID-19, this one is the 15th largest by enrollment, is one of 27 that started in 2020, is one of 17 in phase 3, and was the 18th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 40 studies testing remdesivir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About remdesivir

remdesivir: first FDA approval 2020 (VEKLURY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing remdesivir in COVID-19, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in reducing the rate of of coronavirus disease 2019 (COVID-19) related hospitalization or all-cause death in non-hospitalized participants with early stage COVID-19 and to evaluate the safety of RDV administered in an outpatient setting.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Willing and able to provide written , (individuals ≥ 18 years of age) or assent (individuals ≥ 12 and \< 18 years of age) prior to performing study procedures. Individuals age ≥ 18 years may be enrolled with the consent of a legal representative where permitted according to local law and approved nationally and by the relevant institutional review board (IRB) or independent ethics committee (IEC). For individuals ≥ 12 and \< 18 years of age, a parent or legal guardian must be willing and able to provide written informed consent prior to performing study procedures
  • Either:

    • Age ≥ 18 years (at all sites) or aged ≥ 12 and \< 18 years of age weighing ≥ 40 kg (where permitted according to local law and approved nationally and by the relevant IRB or IEC with at least 1 pre-existing risk factor for progression to hospitalization (chronic lung disease, hypertension, cardiovascular or cerebrovascular disease, diabetes, obesity ( ≥ 30), , chronic mild or moderate kidney disease, chronic liver disease, current cancer, or sickle cell disease)
    • Or aged ≥ 60 years
  • Severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 infection confirmed by molecular diagnosis (nucleic acid (polymerase chain reaction (PCR) or antigen testing) ≤ 4 days prior to screening
  • Presence of ≥ 1 symptom(s) consistent with COVID-19 for ≤ 7 days prior to randomization
  • Not currently requiring hospitalization (hospitalization defined as ≥ 24 hours of acute care)

Key Exclusion Criteria:

  • Participation in any other clinical trial of an experimental treatment and prevention for COVID-19
  • Prior hospitalization for COVID-19
  • Treatment with other agents with actual or possible direct antiviral activity against SARS-CoV-2 or administration of any SARS-CoV-2 (or COVID-19) vaccine
  • Requiring oxygen supplementation

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
584 participants (actual)

Study arms

  • Experimental
    Remdesivir (RDV)

    Participants will receive a single dose of intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2 and 3.

    Drug: RDV

  • Placebo comparator
    Placebo

    Participants will receive IV placebo to match (PTM) RDV on Days 1 to 3.

    Drug: Placebo to Match RDV

Interventions

  • DrugRDV

    Administered as an intravenous infusion

    Also known as: GS-5734™, Veklury®

  • DrugPlacebo to Match RDV

    Administered as an intravenous infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-Cause Death by Day 28

    The composite outcome of COVID-19 related hospitalization (defined as at least 24 hours of acute care) or all-cause death by Day 28 was derived by combining the available all-cause death and COVID-19 related hospitalization reported by the site. The first COVID-19 related hospitalization was used for the percentage of COVID-19 related hospitalization or all-cause death. The percentage of the composite outcome was from the Kaplan-Meier estimate.

    Time frame: Randomization up to Day 28

  2. Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)

    TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date up to last dose date (maximum: 3 days) plus 30 days

Secondary outcomes

  1. Percentage of Participants With COVID-19 Related Medical Visits Attended in Person by the Participant and a Health Care Professional (MAVs) or All-Cause Death by Day 28

    The composite outcome of COVID-19 related MAVs or all-cause death by Day 28 was derived by combining the available all-cause death and COVID-19 related MAVs reported by the site. The percentage of the composite outcome was from the Kaplan-Meier estimate.

    Time frame: Randomization up to Day 28

  2. Percentage of Participants Who Died by Day 28

    Time frame: Randomization up to Day 28

  3. Percentage of Participants With COVID-19 Related Hospitalization at Day 28

    COVID-19 related hospitalization is defined as at least 24 hours of acute care derived by COVID-19 related hospitalization reported by the site. The percentage of the outcome and the corresponding 95% confidence interval were from Kaplan-Meier estimate.

    Time frame: Randomization up to Day 28

  4. Percentage of Participants With COVID-19 Related Hospitalization or All-Cause Death by Day 14

    The composite outcome of COVID-19 related hospitalization (defined as at least 24 hours of acute care) or all-cause death by Day 14 was derived by combining the available all-cause death and COVID-19 related hospitalization reported by the site. The first COVID-19 related hospitalization was used for the percentage of COVID-19 related hospitalization or all-cause death. The percentage of the composite outcome was from the Kaplan-Meier estimate.

    Time frame: Randomization up to Day 14

  5. Percentage of Participants With COVID-19 Related MAVs or All-Cause Death by Day 14

    The composite outcome of COVID-19 related MAVs or all-cause death by Day 14 was derived by combining the available all-cause death and COVID-19 related MAVs reported by the site. The percentage of the composite outcome was from the Kaplan-Meier estimate.

    Time frame: Randomization up to Day 14

  6. Time-Weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load From Baseline to Day 7

    The time-weighted average change from baseline to study Day 7 (DAVG7) in SARS-CoV-2 viral load is defined as the time-weighted average between the first postbaseline value through the last available value up to Day 7 minus the baseline value in SARS-CoV-2 viral load (log10 copies/mL). DAVG7 is calculated using the trapezoidal rule and the area under the curve (AUC). For participants with data through days prior to Day 7, the time-weighted average change used data up to last available timepoint. If there was no postbaseline data, the participant was excluded from the analysis.

    Time frame: Baseline up to Day 7

  7. Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19-adapted Influenza Patient-Reported Outcome Plus Questionnaire (FLU-PRO Plus)

    The COVID-19-adapted FLU-PRO Plus is a questionnaire that assesses the severity of symptoms in participants with COVID-19 across six body systems: nose, throat, eyes, chest/respiratory, gastrointestinal, and body/systemic. Each domain scores range from 0 (symptom free) to 4 (very severe symptoms). A higher score indicates increased symptom severity. Alleviation is defined as symptom scores of 0 (absent) or 1 (mild). Time to alleviation of baseline COVID-19 symptoms is defined (in days) as: First Date of the two consecutive dates achieving alleviation - First dose Date + 1. If a participant had not achieved symptom alleviation at last FLU-PRO Plus assessment or early discontinuation of study, the participant was censored at last FLU-PRO Plus assessment date.

    Time frame: First Dose Date up to Day 14

  8. Percentage of Participants With Worsening After Alleviation of Baseline COVID-19 Symptoms as Reported on the COVID-19-adapted FLU-PRO Plus Questionnaire

    The worsening after alleviation of baseline COVID-19 symptoms is defined as for a participant who has achieved alleviation of baseline COVID-19 symptoms, if symptom scored as 2 or higher at baseline is scored as 2 or higher postbaseline after achieved alleviation, or symptoms scored as 1 at baseline are scored as 1 or higher postbaseline after achieved alleviation. The COVID-19-adapted FLU-PRO Plus was used. It is a questionnaire that assesses the severity of symptoms in participants with COVID-19 across six body systems: nose, throat, eyes, chest/respiratory, gastrointestinal, and body/systemic. Each domain scores range from 0 (symptom free) to 4 (very severe symptoms). A higher score indicates increased symptom severity. Alleviation is defined as symptom scores of 0 (absent) or 1 (mild).

    Time frame: First dose date up to Day 28

  9. Percentage of Participants Who Required Oxygen Supplementation by Day 28

    Time frame: Randomization up to Day 28

07

Results

Posted Nov 16, 2021

Participant flow

Participants were enrolled at study sites in Europe and the United States. The first participant was screened on 18 September 2020. The last study visit occurred on 06 May 2021.

Participant flow — Overall Study
MilestoneRemdesivir (RDV)Placebo
Started292292
Completed266272
Not completed2620
Withdrew: Adverse event03
Withdrew: Investigator's discretion01
Withdrew: Protocol violation11
Withdrew: Withdrew consent54
Withdrew: Lost to follow-up72
Withdrew: Randomized and never treated139

Outcome measures

PrimaryPercentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-Cause Death by Day 28

The composite outcome of COVID-19 related hospitalization (defined as at least 24 hours of acute care) or all-cause death by Day 28 was derived by combining the available all-cause death and COVID-19 related hospitalization reported by the site. The first COVID-19 related hospitalization was used for the percentage of COVID-19 related hospitalization or all-cause death. The percentage of the composite outcome was from the Kaplan-Meier estimate.

Time frame:
Randomization up to Day 28
Reported as:
Number · percentage of participants
Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-Cause Death by Day 28
percentage of participantsRemdesivirPlacebo
Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-Cause Death by Day 280.75.4
Statistical analysis
  • Remdesivir vs Placebo · Regression, Cox · p = 0.0076 · Hazard ratio (hr): 0.134 · 95% CI 0.031 to 0.586Hazard ratio and two-sided 95% confidence interval (CI) were estimated using the Cox regression with baseline stratification factors as covariates.
PrimaryPercentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)

TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date up to last dose date (maximum: 3 days) plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsRemdesivirPlacebo
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)42.346.3
SecondaryPercentage of Participants With COVID-19 Related Medical Visits Attended in Person by the Participant and a Health Care Professional (MAVs) or All-Cause Death by Day 28

The composite outcome of COVID-19 related MAVs or all-cause death by Day 28 was derived by combining the available all-cause death and COVID-19 related MAVs reported by the site. The percentage of the composite outcome was from the Kaplan-Meier estimate.

Time frame:
Randomization up to Day 28
Reported as:
Number · percentage of participants
Percentage of Participants With COVID-19 Related Medical Visits Attended in Person by the Participant and a Health Care Professional (MAVs) or All-Cause Death by Day 28
percentage of participantsRemdesivirPlacebo
Percentage of Participants With COVID-19 Related Medical Visits Attended in Person by the Participant and a Health Care Professional (MAVs) or All-Cause Death by Day 281.78.5
Statistical analysis
  • Remdesivir vs Placebo · Regression, Cox · p = 0.0024 · Hazard ratio (hr): 0.191 · 95% CI 0.065 to 0.555Hazard ratio and two-sided 95% CI were estimated using the Cox regression with baseline stratification factors as covariates.
SecondaryPercentage of Participants Who Died by Day 28
Time frame:
Randomization up to Day 28
Reported as:
Number · percentage of participants
Percentage of Participants Who Died by Day 28
percentage of participantsRemdesivirPlacebo
Percentage of Participants Who Died by Day 2800
SecondaryPercentage of Participants With COVID-19 Related Hospitalization at Day 28

COVID-19 related hospitalization is defined as at least 24 hours of acute care derived by COVID-19 related hospitalization reported by the site. The percentage of the outcome and the corresponding 95% confidence interval were from Kaplan-Meier estimate.

Time frame:
Randomization up to Day 28
Reported as:
Number · percentage of participants
Percentage of Participants With COVID-19 Related Hospitalization at Day 28
percentage of participantsRemdesivirPlacebo
Percentage of Participants With COVID-19 Related Hospitalization at Day 280.7 (0.2 to 2.9)5.4 (3.3 to 8.7)
SecondaryPercentage of Participants With COVID-19 Related Hospitalization or All-Cause Death by Day 14

The composite outcome of COVID-19 related hospitalization (defined as at least 24 hours of acute care) or all-cause death by Day 14 was derived by combining the available all-cause death and COVID-19 related hospitalization reported by the site. The first COVID-19 related hospitalization was used for the percentage of COVID-19 related hospitalization or all-cause death. The percentage of the composite outcome was from the Kaplan-Meier estimate.

Time frame:
Randomization up to Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With COVID-19 Related Hospitalization or All-Cause Death by Day 14
percentage of participantsRemdesivirPlacebo
Percentage of Participants With COVID-19 Related Hospitalization or All-Cause Death by Day 140.75.4
Statistical analysis
  • Remdesivir vs Placebo · Regression, Cox · p = 0.0076 · Hazard ratio (hr): 0.134 · 95% CI 0.031 to 0.586Hazard ratio and two-sided 95% CI were estimated using the Cox regression with baseline stratification factors as covariates.
SecondaryPercentage of Participants With COVID-19 Related MAVs or All-Cause Death by Day 14

The composite outcome of COVID-19 related MAVs or all-cause death by Day 14 was derived by combining the available all-cause death and COVID-19 related MAVs reported by the site. The percentage of the composite outcome was from the Kaplan-Meier estimate.

Time frame:
Randomization up to Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With COVID-19 Related MAVs or All-Cause Death by Day 14
percentage of participantsRemdesivirPlacebo
Percentage of Participants With COVID-19 Related MAVs or All-Cause Death by Day 140.88.0
Statistical analysis
  • Remdesivir vs Placebo · Regression, Cox · p = 0.0019 · Hazard ratio (hr): 0.100 · 95% CI 0.023 to 0.430Hazard ratio and two-sided 95% CI were estimated using the Cox regression with baseline stratification factors as covariates.
SecondaryTime-Weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load From Baseline to Day 7

The time-weighted average change from baseline to study Day 7 (DAVG7) in SARS-CoV-2 viral load is defined as the time-weighted average between the first postbaseline value through the last available value up to Day 7 minus the baseline value in SARS-CoV-2 viral load (log10 copies/mL). DAVG7 is calculated using the trapezoidal rule and the area under the curve (AUC). For participants with data through days prior to Day 7, the time-weighted average change used data up to last available timepoint. If there was no postbaseline data, the participant was excluded from the analysis.

Time frame:
Baseline up to Day 7
Reported as:
Mean · log10 copies/ mililiter (mL)
Time-Weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load From Baseline to Day 7
log10 copies/ mililiter (mL)RemdesivirPlacebo
Time-Weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load From Baseline to Day 7-1.24 ± 1.123-1.14 ± 1.099
Statistical analysis
  • Remdesivir vs Placebo · ANCOVA · p = 0.4318 · Least squares mean: 0.07 · 95% CI -0.10 to 0.24Least squares Mean (LSM), standard error (SE) and 95% CI were from an ANCOVA model with baseline viral load as a covariate.
SecondaryTime to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19-adapted Influenza Patient-Reported Outcome Plus Questionnaire (FLU-PRO Plus)

The COVID-19-adapted FLU-PRO Plus is a questionnaire that assesses the severity of symptoms in participants with COVID-19 across six body systems: nose, throat, eyes, chest/respiratory, gastrointestinal, and body/systemic. Each domain scores range from 0 (symptom free) to 4 (very severe symptoms). A higher score indicates increased symptom severity. Alleviation is defined as symptom scores of 0 (absent) or 1 (mild). Time to alleviation of baseline COVID-19 symptoms is defined (in days) as: First Date of the two consecutive dates achieving alleviation - First dose Date + 1. If a participant had not achieved symptom alleviation at last FLU-PRO Plus assessment or early discontinuation of study, the participant was censored at last FLU-PRO Plus assessment date.

Time frame:
First Dose Date up to Day 14
Reported as:
Median · days
Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19-adapted Influenza Patient-Reported Outcome Plus Questionnaire (FLU-PRO Plus)
daysRemdesivirPlacebo
Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19-adapted Influenza Patient-Reported Outcome Plus Questionnaire (FLU-PRO Plus)NA (10.0 to NA)NA (13.0 to NA)
Statistical analysis
  • Remdesivir vs Placebo · Log Rank · p = 0.2987 · Hazard ratio (hr): 1.405 · 95% CI 0.733 to 2.693Hazard ratio and two-sided 95% CI were estimated using the Cox regression with baseline stratification factors as covariates.
SecondaryPercentage of Participants With Worsening After Alleviation of Baseline COVID-19 Symptoms as Reported on the COVID-19-adapted FLU-PRO Plus Questionnaire

The worsening after alleviation of baseline COVID-19 symptoms is defined as for a participant who has achieved alleviation of baseline COVID-19 symptoms, if symptom scored as 2 or higher at baseline is scored as 2 or higher postbaseline after achieved alleviation, or symptoms scored as 1 at baseline are scored as 1 or higher postbaseline after achieved alleviation. The COVID-19-adapted FLU-PRO Plus was used. It is a questionnaire that assesses the severity of symptoms in participants with COVID-19 across six body systems: nose, throat, eyes, chest/respiratory, gastrointestinal, and body/systemic. Each domain scores range from 0 (symptom free) to 4 (very severe symptoms). A higher score indicates increased symptom severity. Alleviation is defined as symptom scores of 0 (absent) or 1 (mild).

Time frame:
First dose date up to Day 28
Reported as:
Number · percentage of participants
Percentage of Participants With Worsening After Alleviation of Baseline COVID-19 Symptoms as Reported on the COVID-19-adapted FLU-PRO Plus Questionnaire
percentage of participantsRemdesivirPlacebo
Percentage of Participants With Worsening After Alleviation of Baseline COVID-19 Symptoms as Reported on the COVID-19-adapted FLU-PRO Plus Questionnaire30.413.3
SecondaryPercentage of Participants Who Required Oxygen Supplementation by Day 28
Time frame:
Randomization up to Day 28
Reported as:
Number · percentage of participants
Percentage of Participants Who Required Oxygen Supplementation by Day 28
percentage of participantsRemdesivirPlacebo
Percentage of Participants Who Required Oxygen Supplementation by Day 280.41.8
Statistical analysis
  • Remdesivir vs Placebo · Fisher Exact · p = 0.2163

Adverse events

Collected over Adverse Events: First dose date up to 3 days plus 30 days; All-Cause Mortality: Randomization to the end of study (maximum: 59 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Remdesivir0/292 (0%)5/279 (1.8%)48/279 (17.2%)
Placebo1/292 (0.3%)19/283 (6.7%)49/283 (17.3%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventRemdesivirPlacebo
Covid-19 pneumoniaInfections and infestations0/2797/283
PneumoniaInfections and infestations2/2793/283
HypoxiaRespiratory, thoracic and mediastinal disorders0/2793/283
Atrial fibrillationCardiac disorders2/2790/283
Covid-19Infections and infestations1/2792/283
Angina pectorisCardiac disorders1/2791/283
Cardiac failure congestiveCardiac disorders1/2790/283
Viral myocarditisInfections and infestations1/2790/283
Respiratory failureRespiratory, thoracic and mediastinal disorders1/2791/283
Blood pressure inadequately controlledVascular disorders1/2790/283
Most frequent other events
Most frequent other events
EventRemdesivirPlacebo
NauseaGastrointestinal disorders30/27921/283
CoughRespiratory, thoracic and mediastinal disorders10/27918/283
HeadacheNervous system disorders16/27917/283

Baseline characteristics

Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(Years)RemdesivirPlaceboTotal
Mean50 ± 15.351 ± 14.850 ± 15.1
Sex: Female, Male
Sex: Female, Male(Participants)RemdesivirPlaceboTotal
Female131138269
Male148145293
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RemdesivirPlaceboTotal
Race — American Indian or Alaska Native152136
Race — Asian6713
Race — Black202242
Race — Native Hawaiian or Pacific Islander101
Race — White228224452
Race — Other325
Race — Not Permitted6713
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RemdesivirPlaceboTotal
Ethnicity — Hispanic or Latino123112235
Ethnicity — Not Hispanic or Latino146158304
Ethnicity — Not Permitted101323
Region of Enrollment
Region of Enrollment(Participants)RemdesivirPlaceboTotal
United States264267531
Denmark5510
United Kingdom314
Spain71017
08

Study locations

104 sites
  • Arizona Liver Health
    Chandler, Arizona 85224, United States
  • Arizona Clinical Trials
    Tucson, Arizona 85712, United States
  • St Joseph Hospital Eureka
    Eureka, California 95501, United States
  • St. Joseph Heritage Healthcare
    Fullerton, California 92385, United States
  • Elevated Health
    Huntington Beach, California 92648, United States
  • Ruane Clinical Research Group
    Los Angeles, California 90036, United States
  • LA Universal Center, INC.
    Los Angeles, California 90057, United States
  • Mills Clinical Research
    Los Angeles, California 90069, United States
  • Kaiser Permanente Northern California
    Oakland, California 94611, United States
  • FOMAT Medical Research
    Oxnard, California 93030, United States
  • UC Davis Health
    Sacramento, California 95817, United States
  • Kaiser Permanente Northern California, 6600 Bruceville Road
    Sacramento, California 95823, United States
  • Kaiser Permanente Northern California, 2025 Morse Ave
    Sacramento, California 95825, United States
  • Kaiser Permanente Northern California, 1200 El Camino Real
    San Francisco, California 94080, United States
  • Kaiser Permanente Northern California, 2425 Geary Blvd
    San Francisco, California 94115, United States
  • UCSF Medical Center
    San Francisco, California 94143, United States
  • Kaiser Permanente Northern California, 250 Hospital Parkway, Suite 850
    San Jose, California 95119, United States
  • Kaiser Permanente Northern California, 2500 Merced St
    San Leandro, California 94577, United States
  • St. Joseph Heritage Healthcare
    Santa Rosa, California 95403, United States
  • Premiere Medical Center of Burbank, Inc
    Toluca Lake, California 91602, United States
  • Kaiser Permanente Northern California, 975 Sereno Drive
    Vallejo, California 94589, United States
  • New Hope Research Development DBA HCD
    Whittier, California 90603, United States
  • Centura Health Porter Place
    Denver, Colorado 80210, United States
  • Nuvance Health
    Danbury, Connecticut 06810, United States
  • RecioMed Clinical Research Network
    Boynton Beach, Florida 33472, United States
  • Midland Florida Clinical Research Center, LLC
    DeLand, Florida 32720, United States
  • Invesclinic
    Fort Lauderdale, Florida 33308, United States
  • Lawnwood Regional Medical Center
    Fort Pierce, Florida 34982, United States
  • Evolution Clinical Trials
    Hialeah Gardens, Florida 33016, United States
  • Encore Medical Research
    Hollywood, Florida 33201, United States
  • Advanced Pulmonary Research Institute
    Loxahatchee Groves, Florida 33470, United States
  • L&C Professional Medical Research Institute
    Miami, Florida 33144, United States
  • Laguna Clinical Research Associates
    Miami, Florida 33144, United States
  • CTMD Research, Inc
    Palm Springs, Florida 33406, United States
  • IMIC Inc
    Palmetto Bay, Florida 33157, United States
  • Luminous Clinical Research - South Florida Urgent Care
    Pembroke Pines, Florida 33029, United States
  • St. Josephs Comprehensive Research Institute
    Tampa, Florida 33614, United States
  • AIDS Research and Treatment Center of the Treasure Coast
    Vero Beach, Florida 32960, United States
  • Triple O Research Institute PA
    West Palm Beach, Florida 33401, United States
  • Agile Clinical Research Trials
    Atlanta, Georgia 30328, United States
  • Mercer University School of Medicine
    Macon, Georgia 31210, United States
  • Infectious Disease Associates of Kansas City, P.C.Infectious Disease Associates of Kansas City, P.C.
    Burr Ridge, Illinois 60527, United States
  • Metro Infectious Disease Consultants
    Burr Ridge, Illinois 60527, United States
  • NorthStar Medical Center
    Chicago, Illinois 60657, United States
  • NorthShore University Healthsystem
    Evanston, Illinois 60201, United States
  • Tulane University
    New Orleans, Louisiana 70112, United States
  • Holy Cross Hospital, Inc.
    Baltimore, Maryland 21201, United States
  • University of Maryland Baltimore
    Baltimore, Maryland 21201, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • South Shore Hospital
    South Weymouth, Massachusetts 02190, United States
  • VA Boston Healthcare System
    West Roxbury, Massachusetts 02132, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • Onyx Research Institute
    Flint, Michigan 48532, United States
  • Memorial Hospital of Gulfport
    Gulfport, Mississippi 39501, United States
  • Metro Infectious Disease Consultants
    Kansas City, Missouri 64132, United States
  • Quality Clinical Research Inc.
    Omaha, Nebraska 68114, United States
  • AB Clinical Trials
    Las Vegas, Nevada 89119, United States
  • AXCES Research Group
    Santa Fe, New Mexico 87505, United States
  • New York Presbyterian Hospital
    Flushing, New York 11355, United States
  • Northwell Health
    New Hyde Park, New York 11040, United States
  • Atrium Health Carolinas Medical Center
    Charlotte, North Carolina 28209, United States
  • East Carolina University
    Greenville, North Carolina 27858, United States
  • Rosedale Infectious Diseases
    Huntersville, North Carolina 28078, United States
  • Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Cherokee Nation WW Hastings Hospital
    Tahlequah, Oklahoma 74464, United States
  • Providence St. Vincent Medical Center
    Portland, Oregon 92775, United States
  • Temple University
    Philadelphia, Pennsylvania 19140, United States
  • Avera Research Institute
    Sioux Falls, South Dakota 57108, United States
  • University of Tennessee Health Science Center
    Knoxville, Tennessee 37920, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • UT Physicians
    Bellaire, Texas 77401, United States
  • Baylor University Medical Center, 700 Scott and White Dr.
    College Station, Texas 77845, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Care United Research, LLC
    Forney, Texas 75126, United States
  • VIP Trials
    Harlingen, Texas 78550, United States
  • University of Texas
    Houston, Texas 77030, United States
  • The Crofoot Research Center, Inc
    Houston, Texas 77098, United States
  • Baylor University Medical Center, 1901 North McArthur Blvd
    Irving, Texas 75061, United States
  • Laguna Clinical Research Associates
    Laredo, Texas 78041, United States
  • Diagnostic Clinic of Longview - Center for Clinical Research
    Longview, Texas 75605, United States
  • STAAMP Research
    San Antonio, Texas 78229, United States
  • Sugar Lakes Family Practice
    Sugar Land, Texas 77479, United States
  • Baylor University Medical Center, 2201 MacArthur Dr., Suite 100
    Waco, Texas 76708, United States
  • ClinPoint Trials
    Waxahachie, Texas 75165, United States
  • Intermountain Healthcare
    Murray, Utah 84107, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23249, United States
  • Providence Regional Medical Center Everett
    Everett, Washington 98201, United States
  • Sound Medical Research
    Port Orchard, Washington 98366, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Providence Medical Research Center
    Spokane, Washington 99204, United States
  • Wisconsin Corporation for Biomedical Research
    Milwaukee, Wisconsin 53295, United States
  • Aalborg University Hospital
    Aalborg, DK9000, Denmark
  • Aarhus University Hospital
    Aarhus N, 8200, Denmark
  • Rigshospitalet
    Copenhagen, 2100, Denmark
  • Hvidovre Hospital
    Hvidovre, 2650, Denmark
  • Odense University Hospital
    Odense, DK5000, Denmark
  • Hospital Universitari Germans Trias i Pujol
    Badalona, 08916, Spain
  • Hospital Clinic
    Barcelona, 08036, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, 28031, Spain

Showing the first 100 of 104 sites across 4 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA; GS-US-540-9012 (PINETREE) Investigators. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22. PubMed 34937145 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in May 2021, 7 months.

Results were first posted in Nov 2021, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2020
First posted
Aug 6, 2020
StartActual
Sep 18, 2020
Primary completionActual
May 6, 2021
CompletionActual
May 6, 2021
Results first posted
Nov 16, 2021
Last update
Nov 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04501952
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 6, 2020
Start date
Sep 18, 2020
Primary completion
May 6, 2021
Completion
May 6, 2021
Results posted
Nov 16, 2021
Last update
Nov 16, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remdesivir

Start the discussion